4. Absci Corporation (NASDAQ:ABSI)
Number of Hedge Fund Holders: 39
Market Capitalization: $1.42 billion
Share Price: $8.25
Absci Corporation (NASDAQ: ABSI) has attracted attention through its generative AI-designed biologics platform and an advancing internal pipeline. According to the supplied data, the stock had gained more than 180% in 2026, making it another strong performer among the biotechnology companies screened for this article.
The lead focus is ABS-201, an investigational antibody targeting the prolactin receptor. Its development program includes pattern hair loss, with endometriosis representing a separate potential application.
Early clinical findings require careful interpretation. The interim Phase 1 update described favorable safety and tolerability observations and an estimated half-life of at least 65 days. Those findings support further development and the possibility of infrequent dosing, but they do not establish durable hair-growth efficacy.
The company planned additional proof-of-concept results, giving investors a more direct test of the treatment’s commercial promise. A successful program would need to demonstrate meaningful benefits alongside an acceptable safety profile and a practical dosing schedule.
Financing strengthened the balance sheet. A $100 million offering included a $40 million strategic investment from a major pharmaceutical company. Cash, cash equivalents, and marketable securities totaled $201.1 million at June 30, with management projecting funding into the second half of 2028.
KeyBanc reiterated a Buy rating and a $20 price target on October 16. JPMorgan raised its target to $15 from $14 on October 12 while maintaining an Overweight rating.
The under-$10 classification uses the October 27 price above; the separate $11.13 quote in the supplied material was undated.
Ranking rationale: Absci Corporation (NASDAQ: ABSI) takes fourth place with 39 hedge-fund holders. Its AI-designed therapeutic pipeline and strengthened funding support inclusion, while upcoming efficacy evidence remains central to assessing the value behind investor enthusiasm.
